Status:
UNKNOWN
Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
Lead Sponsor:
Wolfson Medical Center
Conditions:
Multiple Myeloma
Peripheral Neuropathy
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
In the present study we are planning to study electrophysiological changes related to the dose and time of bortezomib administration in newly diagnosed patients with MM, during the first months of tre...
Eligibility Criteria
Inclusion
- Age\> 18
- Patients with Multiple Myeloma stage II, III (Durie and Salmon staging) prior to Bortezomib Therapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Be willing and able to comply with the protocol treatment for the duration of the study
- Patient's written informed consent
Exclusion
- Multiple Myeloma on progression
- Incidence of Relapsed or Refractory Myeloma
- Patients with the existing neuropathy at the time of the diagnosis
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00872352
Start Date
April 1 2009
End Date
August 1 2009
Last Update
March 31 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wolfson MC
Holon, Holon, Israel, 58100